GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (OTCPK:LDXHF) » Definitions » Total Assets

LDXHF (Lumos Diagnostics Holdings) Total Assets : $26.49 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Total Assets?

Lumos Diagnostics Holdings's Total Assets for the quarter that ended in Dec. 2024 was $26.49 Mil.

During the past 12 months, Lumos Diagnostics Holdings's average Total Assets Growth Rate was 2.20% per year.

Total Assets is connected with ROA %. Lumos Diagnostics Holdings's annualized ROA % for the quarter that ended in Dec. 2024 was -21.03%. Total Assets is also linked to Revenue through Asset Turnover. Lumos Diagnostics Holdings's Asset Turnover for the quarter that ended in Dec. 2024 was 0.24.

Lumos Diagnostics Holdings Total Assets Historical Data

The historical data trend for Lumos Diagnostics Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Total Assets Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23 Jun24
Total Assets
36.94 25.42 26.84

Lumos Diagnostics Holdings Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Assets Get a 7-Day Free Trial 25.02 25.42 23.05 26.84 26.49

Lumos Diagnostics Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Lumos Diagnostics Holdings's Total Assets for the fiscal year that ended in Jun. 2024 is calculated as

Total Assets=Total Equity (A: Jun. 2024 )+Total Liabilities (A: Jun. 2024 )
=7.109+19.729
=26.84

Lumos Diagnostics Holdings's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=9.79+16.704
=26.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumos Diagnostics Holdings  (OTCPK:LDXHF) Total Assets Explanation

Total Assets is connected with ROA %.

Lumos Diagnostics Holdings's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-5.608/( (26.838+26.494)/ 2 )
=-5.608/26.666
=-21.03 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Lumos Diagnostics Holdings's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=6.306/( (26.838+26.494)/ 2 )
=6.306/26.666
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Lumos Diagnostics Holdings Total Assets Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lumos Diagnostics Holdings Ltd (OTCPK:LDXHF) » Definitions » Total Assets
Comparable Companies
ASX:HMD ASX:UBI ASX:CBL ASX:OSL ASX:AT1 ASX:ADRDA ASX:UCM ASX:IRX ASX:EYE ASX:NTI ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
LDX:Australia
Address
2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Website
https://www.lumosdiagnostics.com
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services, and it operates across two geographical regions, the United States and Australia. and the majority of revenue is generated from the United States.

Lumos Diagnostics Holdings Headlines

From GuruFocus

Dr. Jerome Adams, Former U.S. Surgeon General, Joins Lumos Diagnostics as a Strategic Healthcare Adviser

By Business Wire Business Wire • 09-14-2021

Economic Evaluation of Lumos Diagnostics' FebriDx� Point-of-Care Test Highlights $2.5 Billion in Potential U.S. Healthcare Cost Savings Annually

By Business Wire Business Wire • 10-06-2021

Lumos Diagnostics Receives Authorization for CoviDx� SARS-CoV-2 Rapid Antigen Test in Canada

By Business Wire Business Wire • 11-03-2021

Lumos Diagnostics Raises $63M AUD in ASX IPO

By Business Wire Business Wire • 07-08-2021

Lumos Diagnostics FY21 Full Year Results

By Business Wire Business Wire • 08-31-2021